<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet13269</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-13269</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Скрининг синдрома Кушинга у пациентов с морбидным ожирением и сахарным диабетом 2 типа перед бариатрическими операциями</article-title><trans-title-group xml:lang="en"><trans-title>Screening for Cushing's syndrome in patients with morbid obesity and type 2 diabetes before bariatric surgery</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5407-8722</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Климонтов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Klimontov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Климонтов Вадим Валерьевич, д.м.н., профессор</p><p>Researcher ID: R-7689-2017; Scopus Author ID: 8295977000</p><p>630060, Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Vadim V. Klimontov, MD, PhD, Professor</p><p>Researcher ID: R-7689-2017; Scopus Author ID: 8295977000</p><p>2, Timakov Str., Novosibirsk, 630060</p></bio><email xlink:type="simple">klimontov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8629-7030</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Королева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Koroleva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Королева Елена Анатольевна , к.м.н., ст.н.с.</p><p>Scopus Author ID: 55522435000</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Elena A. Koroleva, MD, PhD</p><p>Scopus Author ID: 55522435000</p><p>Novosibirsk</p></bio><email xlink:type="simple">ekoro@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-1998-7097</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивайкин</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivaikin</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ивайкин Никита Владимирович , клинический ординатор</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Nikita V. Ivaikin, MD</p><p>Novosibirsk</p></bio><email xlink:type="simple">n.ivaikin@g.nsu.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт клинической и экспериментальной лимфологии филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук» (НИИКЭЛ филиал ИЦиГ СО РАН) ; Новосибирский национальный государственный исследовательский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Clinical and Experimental Lymphology Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (RICEL Branch of IC&amp;G SB RAS); Novosibirsk State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт клинической и экспериментальной лимфологии филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук» (НИИКЭЛ филиал ИЦиГ СО РАН)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Clinical and Experimental Lymphology Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (RICEL Branch of IC&amp;G SB RAS)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Новосибирский национальный государственный исследовательский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>18</day><month>07</month><year>2026</year></pub-date><volume>23</volume><issue>2</issue><fpage>54</fpage><lpage>60</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Климонтов В.В., Королева Е.А., Ивайкин Н.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Климонтов В.В., Королева Е.А., Ивайкин Н.В.</copyright-holder><copyright-holder xml:lang="en">Klimontov V.V., Koroleva E.A., Ivaikin N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/13269">https://www.omet-endojournals.ru/jour/article/view/13269</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Бариатрическая хирургия представляет собой наиболее эффективный метод лечения морбидного ожирения и сахарного диабета 2 типа (CД2). Гиперкортизолизм у пациентов, подвергающихся бариатрическим операциям, может снижать эффективность хирургии и увеличивать риск осложнений.</p></sec><sec><title>Цель</title><p>Цель. Оценить распространенность и клинические формы гиперкортизолизма у пациентов с морбидным ожирением и СД2, проходящих обследование перед бариатрическими вмешательствами.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен скрининг синдрома Кушинга у пациентов с морбидным ожирением и СД2, направленных на обследование в клинику перед бариатрическими операциями. В качестве теста первой линии использован ночной супрессивный дексаметазоновый тест с 1 мг дексаметазона (НДТ). В качестве дополнительных тестов применяли исследование суточной экскреции свободного кортизола с мочой, исследование уровня кортизола в 23 ч. в слюне или в сыворотке крови. При патологических результатах тестов второй линии исследовали уровень АКТГ, проводили тест с 8 мг дексаметазона.</p></sec><sec><title>Результаты</title><p>Результаты. В исследование включен 91 пациент, 21 мужчина и 70 женщин в возрасте от 27 до 66 лет. Снижение уровня кортизола &lt;50 нмоль/л в НДТ зафиксировано у 75 человек. У остальных пациентов концентрация кортизола превышала точку разделения, что потребовало дальнейших исследований. У 14 (15,4%) пациентов c функциональным гиперкортизолизмом («псевдоКушинг») уровень кортизола в НДТ находился в диапазоне от 50 до 140 нмоль/л (медиана 67,7). У трех женщин уровень кортизола в НДТ демонстрировал очень высокие значения (593, 461 и 425 нмоль/л). При дальнейшем обследовании у двух из них верифицированы аденомы гипофиза, у третьей выявлены аденомы в обоих надпочечниках.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные результаты подтверждают необходимость скрининга гиперкортизолизма у всех пациентов с морбидным ожирением и СД2 перед бариатрическими вмешательствами.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: Bariatric surgery is the most effective treatment for morbid obesity and type 2 diabetes. Hypercortisolism in patients undergoing bariatric surgery may reduce the effectiveness of surgery and increase the risk of complications. </p></sec><sec><title>AIM</title><p>AIM: To assess the prevalence and clinical forms of hypercortisolism in patients with morbid obesity and type 2 diabetes mellitus undergoing examination before bariatric interventions.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: Screening for Cushing's syndrome was performed in patients with morbid obesity and type 2 diabetes mellitus referred to the clinic for examination before bariatric surgery. The overnight dexamethasone suppressive test with 1 mg dexamethasone (1-mg DST) was used as a first-line test. Additional tests included 24-hour urinary free cortisol excretion and evening cortisol level in saliva or blood serum. In case of pathological results of the second-line tests, the ACTH level was measured, and suppressive test with 8 mg dexamethasone was performed.</p></sec><sec><title>RESULTS</title><p>RESULTS: The study included 91 patients, 21 men and 70 women, aged 27 to 66 years. A decrease in the cortisol level &lt;50 nmol/l in the 1-mg DST was recorded in 75 patients. In the remaining subjects, the cortisol concentration exceeded the cutoff point, which required further tests. In 14 patients (15.4%) with functional hypercortisolism (pseudo-Cushing`s syndrome), the cortisol level in 1-mg DST ranged from 50 to 140 nmol/l (median 67.7). In three women, the cortisol level in the 1-mg DST demonstrated very high values (593, 461 and 425 nmol/l). During further examination, pituitary adenomas were verified in two of them, and the third woman was diagnosed with adenomas in both adrenal glands.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: The obtained results confirm the need for screening for hypercortisolism in all patients with morbid obesity and type 2 diabetes scheduled for bariatric surgery.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>бариарическая хирургия</kwd><kwd>синдром Кушинга</kwd><kwd>гиперкортизолизм</kwd><kwd>супрессивный тест с дексаметазоном</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>type 2 diabetes</kwd><kwd>bariatric surgery</kwd><kwd>Cushing's syndrome</kwd><kwd>hypercortisolism</kwd><kwd>dexamethasone suppressive test</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено за счет средств госзадания НИИКЭЛ — филиал ИЦиГ СО РАН.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zang X, Lin T, Ma J, et al. Comparison of Benefits and Risks of Metabolic Surgery for Long-Term (5 Years) Weight Loss and Diabetes Remission in Overweight/Obese Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized Trials. Diabetes Metab Res Rev. 2025;41(3):e70033. doi: https://doi.org/10.1002/dmrr.70033</mixed-citation><mixed-citation xml:lang="en">Zang X, Lin T, Ma J, et al. Comparison of Benefits and Risks of Metabolic Surgery for Long-Term (5 Years) Weight Loss and Diabetes Remission in Overweight/Obese Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized Trials. Diabetes Metab Res Rev. 2025;41(3):e70033. doi: https://doi.org/10.1002/dmrr.70033</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Y, Miao C, Wang Y, He J. The long-term effect of bariatric/metabolic surgery versus pharmacologic therapy in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2024;40(5):e3830. doi: https://doi.org/10.1002/dmrr.3830</mixed-citation><mixed-citation xml:lang="en">Yang Y, Miao C, Wang Y, He J. The long-term effect of bariatric/metabolic surgery versus pharmacologic therapy in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2024;40(5):e3830. doi: https://doi.org/10.1002/dmrr.3830</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021;397(10287):1830-1841. doi: https://doi.org/10.1016/S0140-6736(21)00591-2</mixed-citation><mixed-citation xml:lang="en">Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021;397(10287):1830-1841. doi: https://doi.org/10.1016/S0140-6736(21)00591-2</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Белая Ж.Е., Воронцов А.В., Ильин А.В., и др. Эндогенный гиперкортицизм среди пациентов с ожирением: причина или конкурирующее заболевание. // Ожирение и метаболизм. — 2016. — Т. 13. — №1. — С. 57-61. doi: https://doi.org/10.14341/omet2016157-61</mixed-citation><mixed-citation xml:lang="en">Belaya ZhE, Vorontsov AV, Il'in AV, et al. Endogenous hypercortisolism in the patient with obesity: the cause or a competing disorder. Obesity and Metabolism. 2016;13(1):57-61. (In Russ.) doi: https://doi.org/10.14341/omet2016157-61</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Varlamov EV, Vila G, Fleseriu M. Perioperative Management of a Patient With Cushing Disease. J Endocr Soc. 2022;6(3):bvac010. doi: https://doi.org/10.1210/jendso/bvac010</mixed-citation><mixed-citation xml:lang="en">Varlamov EV, Vila G, Fleseriu M. Perioperative Management of a Patient With Cushing Disease. J Endocr Soc. 2022;6(3):bvac010. doi: https://doi.org/10.1210/jendso/bvac010</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Akalestou E, Genser L, Rutter GA. Glucocorticoid Metabolism in Obesity and Following Weight Loss. Front Endocrinol (Lausanne). 2020;11:59. doi: https://doi.org/10.3389/fendo.2020.00059</mixed-citation><mixed-citation xml:lang="en">Akalestou E, Genser L, Rutter GA. Glucocorticoid Metabolism in Obesity and Following Weight Loss. Front Endocrinol (Lausanne). 2020;11:59. doi: https://doi.org/10.3389/fendo.2020.00059</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Moisan MP, Castanon N. Emerging Role of Corticosteroid-Binding Globulin in Glucocorticoid-Driven Metabolic Disorders. Front Endocrinol (Lausanne). 2016;7:160. doi: https://doi.org/10.3389/fendo.2016.00160</mixed-citation><mixed-citation xml:lang="en">Moisan MP, Castanon N. Emerging Role of CorticosteroidBinding Globulin in Glucocorticoid-Driven Metabolic Disorders. Front Endocrinol (Lausanne). 2016;7:160. doi: https://doi.org/10.3389/fendo.2016.00160</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yavuz DG, Apaydin T, Gunhan HG, Uygur MM. Assessment of 1 mg Dexamethasone Suppression Test in Patients with Obesity Before Bariatric Surgery. Obes Surg. 2020;30(12):4981-4985. doi: https://doi.org/10.1007/s11695-020-04865-x</mixed-citation><mixed-citation xml:lang="en">Yavuz DG, Apaydin T, Gunhan HG, Uygur MM. Assessment of 1 mg Dexamethasone Suppression Test in Patients with Obesity Before Bariatric Surgery. Obes Surg. 2020;30(12):4981-4985. doi: https://doi.org/10.1007/s11695-020-04865-x</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Muraca E, Ciardullo S, Perra S, et al. Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment. Diabetes Metab Res Rev. 2021;37(3):e3389. doi: https://doi.org/10.1002/dmrr.3389</mixed-citation><mixed-citation xml:lang="en">Muraca E, Ciardullo S, Perra S, et al. Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment. Diabetes Metab Res Rev. 2021;37(3):e3389. doi: https://doi.org/10.1002/dmrr.3389</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guarnotta V, Giordano C, Reimondo G. Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesity. J Endocrinol Invest. 2025;48(Suppl 1):47-59. doi: https://doi.org/10.1007/s40618-024-02455-7. Erratum in: J Endocrinol Invest. 2025;48(Suppl 1):61. doi: https://doi.org/10.1007/s40618-024-02487-z</mixed-citation><mixed-citation xml:lang="en">Guarnotta V, Giordano C, Reimondo G. Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesity. J Endocrinol Invest. 2025;48(Suppl 1):47-59. doi: https://doi.org/10.1007/s40618-024-02455-7. Erratum in: J Endocrinol Invest. 2025;48(Suppl 1):61. doi: https://doi.org/10.1007/s40618-024-02487-z</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Favero V, Cremaschi A, Parazzoli C, et al. Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside. Int J Mol Sci. 2022;23(2):673. doi: https://doi.org/10.3390/ijms23020673</mixed-citation><mixed-citation xml:lang="en">Favero V, Cremaschi A, Parazzoli C, et al. Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside. Int J Mol Sci. 2022;23(2):673. doi: https://doi.org/10.3390/ijms23020673</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Болезнь Иценко-Кушинга. / Под ред. Дедова И.И., Мельниченко Г.А. – М.: УП Принт; 2011.</mixed-citation><mixed-citation xml:lang="en">Itsenko-Cushing's disease. / Edited by Dedov I.I., Melnichenko G.A. - M.: UP Print; 2011. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Turney HG. Discussion on Disease of the Pituitary Body. Proc R Soc Med. 1913;6(Neurol Sect):lxix-lxxviii. doi: https://doi.org/10.1177/003591571300600856</mixed-citation><mixed-citation xml:lang="en">Turney HG. Discussion on Disease of the Pituitary Body. Proc R Soc Med. 1913;6(Neurol Sect):lxix-lxxviii. doi: https://doi.org/10.1177/003591571300600856</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Parasiliti-Caprino M, Bioletto F, Frigerio T, et al. A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. Front Endocrinol (Lausanne). 2021;12:747549. doi: https://doi.org/10.3389/fendo.2021.747549</mixed-citation><mixed-citation xml:lang="en">Parasiliti-Caprino M, Bioletto F, Frigerio T, et al. A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. Front Endocrinol (Lausanne). 2021;12:747549. doi: https://doi.org/10.3389/fendo.2021.747549</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Javorsky BR, Carroll TB, Tritos NA, Salvatori R, Heaney AP, Fleseriu M, Biller BM, Findling JW. Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients. Obes Surg. 2015;25(12):2306-13. doi: https://doi.org/10.1007/s11695-015-1681-z</mixed-citation><mixed-citation xml:lang="en">Javorsky BR, Carroll TB, Tritos NA, Salvatori R, Heaney AP, Fleseriu M, Biller BM, Findling JW. Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients. Obes Surg. 2015;25(12):2306-13. doi: https://doi.org/10.1007/s11695-015-1681-z</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed SF, Mahmood SW, Ismaeil DA, Baba HO, Salih KM, et al. Challenges of Cushing's syndrome and bariatric surgery: a case report with literature review. J Surg Case Rep. 2025;2025(6):rjaf366. doi: https://doi.org/10.1093/jscr/rjaf366</mixed-citation><mixed-citation xml:lang="en">Ahmed SF, Mahmood SW, Ismaeil DA, Baba HO, Salih KM, et al. Challenges of Cushing's syndrome and bariatric surgery: a case report with literature review. J Surg Case Rep. 2025;2025(6):rjaf366. doi: https://doi.org/10.1093/jscr/rjaf366</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Borsoi L, Ludvik B, Prager G, Luger A, Riedl M. Cushing's syndrome in a morbidly obese patient undergoing evaluation before bariatric surgery. Obes Facts. 2014;7(3):191-6. doi: https://doi.org/10.1159/000363260</mixed-citation><mixed-citation xml:lang="en">Borsoi L, Ludvik B, Prager G, Luger A, Riedl M. Cushing's syndrome in a morbidly obese patient undergoing evaluation before bariatric surgery. Obes Facts. 2014;7(3):191-6. doi: https://doi.org/10.1159/000363260</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Шестакова М.В., и др. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-й пересмотр (лечение морбидного ожирения у взрослых). // Ожирение и метаболизм. — 2018. — Т. 15. — №1. — С. 53-70. doi: https://doi.org/10.14341/omet2018153-70</mixed-citation><mixed-citation xml:lang="en">Dedov II, Mel'nichenko GA, Shestakova MV, et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and Metabolism. 2018;15(1):53-70. (In Russ.) doi: https://doi.org/10.14341/omet2018153-70</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines For The Perioperative Nutrition, Metabolic, And Nonsurgical Support Of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored By American Association Of Clinical Endocrinologists/American College Of Endocrinology, The Obesity Society, American Society For Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, And American Society Of Anesthesiologists - Executive Summary. Endocr Pract. 2019;25(12):1346-1359. doi: https://doi.org/10.4158/GL-2019-0406</mixed-citation><mixed-citation xml:lang="en">Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines For The Perioperative Nutrition, Metabolic, And Nonsurgical Support Of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored By American Association Of Clinical Endocrinologists/American College Of Endocrinology, The Obesity Society, American Society For Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, And American Society Of Anesthesiologists - Executive Summary. Endocr Pract. 2019;25(12):1346-1359. doi: https://doi.org/10.4158/GL-2019-0406</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Şirikçi V, Kiraç CO, Findikli HA, Muhammedoğlu B. Assessing the predictive value of the suppressed 1 mg overnight dexamethasone suppression test in success of bariatric surgery. Medicine (Baltimore). 2024;103(28):e38939. doi: https://doi.org/10.1097/MD.0000000000038939</mixed-citation><mixed-citation xml:lang="en">Şirikçi V, Kiraç CO, Findikli HA, Muhammedoğlu B. Assessing the predictive value of the suppressed 1 mg overnight dexamethasone suppression test in success of bariatric surgery. Medicine (Baltimore). 2024;103(28):e38939. doi: https://doi.org/10.1097/MD.0000000000038939</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Casteràs A, Fidilio E, Comas M, et al. Pre-Surgery Cortisol Levels as Biomarker of Evolution after Bariatric Surgery: Weight Loss and Weight Regain. J Clin Med. 2024;13(17):5146. doi: https://doi.org/10.3390/jcm13175146</mixed-citation><mixed-citation xml:lang="en">Casteràs A, Fidilio E, Comas M, et al. Pre-Surgery Cortisol Levels as Biomarker of Evolution after Bariatric Surgery: Weight Loss and Weight Regain. J Clin Med. 2024;13(17):5146. doi: https://doi.org/10.3390/jcm13175146</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
